Dalbavancin is a new glycopeptide anti-MRSA* antibiotic. Compared to existing glycopeptides anti-MRSA antibiotics, it has better antibiotic strength and, because it only needs to be taken once a week, it will be easier for both patients and medical care providers. It also offers stable absorption and metabolism for patients with light to moderate kidney and liver dysfunction. We know that its interactions with other medications are extremely small, and it is proving to be very safe in clinical trials.

*MRSA: Methicillin-Resistant Staphylococcus Aureus

This program is the subject of a rights transfer agreement with Durata Therapeutics, Inc. For details, see the Licensing Status link.